by divibasicbldev | Jan 8, 2024 | Press Releases
— Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 — — Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio — SOUTH SAN FRANCISCO, Calif. and MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) —...
by divibasicbldev | Jan 2, 2024 | Press Releases
— PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials — — Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – — Initial readout expected as early as Q3...
by divibasicbldev | Dec 28, 2023 | Press Releases
SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 28, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA) today announced that its meeting of stockholders, which had been partially adjourned on...
by divibasicbldev | Dec 19, 2023 | Press Releases
— Solicitation Continues for Certain Charter Amendment Proposals -SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that...
by divibasicbldev | Dec 11, 2023 | Press Releases
— Preclinical data continues to demonstrate PAS-004’s potentially superior properties as compared to FDA approved MEK inhibitors — — Once daily dose of PAS-004 delivers anti-tumor efficacy in in vivo NRAS mutation cancer models — SOUTH...
by divibasicbldev | Nov 29, 2023 | Press Releases
SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that its annual meeting of stockholders held on November 29, 2023 (the...
